The myth of measurable disease in ovarian cancer: revisited.
There are well-documented and serious limitations associated with analyzing measurable disease in ovarian cancer as a sole primary endpoint in clinical trials, as this focus requires the presence of individual tumor masses of sufficient size and distinctive shape to image. An alternative highly rational strategy adds the routine monitoring of validated serum tumor markers (e.g., CA-125), which can more adequately define changes in "tumor volume" associated with small nonvisualized macroscopic and diffuse microscopic cancer.
Markman
Maurie
M
Department of Gynecologic Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA. mmarkman@mdanderson.org
D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis*; D011237:Predictive Value of Tests
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen